Singh groups reported a novel hybrid analogue of monastrol-1,3,5-triazine 10 as an effective anti-breast cancer agent [14] in 2017, which showed excellent EGFR-TK enzyme inhibitory activity (96.3% at 10 μM). This evidence concerns the gene EGFR and breast cancer.